Tax-withholding sale by Acumen (NASDAQ: ABOS) chief regulatory officer

Rhea-AI Filing Summary

Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, reported an automatic sale of company stock tied to tax withholding. On 01/07/2026, she sold 1,097 shares of Acumen common stock at a weighted average price of $1.9838 per share. The shares were sold under a pre-arranged Rule 10b5-1 trading plan and were executed as a “sell to cover” transaction to satisfy tax withholding obligations from the vesting of restricted stock units.

After this transaction, Schacterle beneficially owns 7,703 shares of Acumen common stock. A Rule 10b5-1 plan allows insiders to schedule trades in advance, which can help separate routine tax-related or liquidity transactions from discretionary trading decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schacterle Amy

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S		1,097(1)	D	$1.9838(2)	7,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acumen Pharmaceuticals (ABOS) report?

Acumen Pharmaceuticals reported that its Chief Regulatory Officer, Amy Schacterle, sold 1,097 shares of common stock on 01/07/2026. The sale was disclosed on a Form 4 filing.

Why did Amy Schacterle sell 1,097 shares of ABOS stock?

The 1,097 shares were sold through an automatic “sell to cover” transaction to satisfy tax withholding obligations related to the vesting of restricted stock units, as described in the footnotes.

At what price were the Acumen (ABOS) shares sold in this Form 4?

The filing reports a weighted average sales price of $1.9838 per share. The shares were sold in multiple trades at prices ranging from $1.9550 to $2.0100.

How many Acumen Pharmaceuticals (ABOS) shares does Amy Schacterle own after the sale?

Following the reported transaction, Amy Schacterle beneficially owns 7,703 shares of Acumen Pharmaceuticals common stock in direct ownership.

Was the Acumen (ABOS) insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was made under a Rule 10b5-1 trading plan that Amy Schacterle adopted on September 30, 2025, as noted in the footnotes to the Form 4.

Is this Acumen (ABOS) insider transaction discretionary or pre-arranged?

The transaction is described as an automatic “sell to cover” under a pre-arranged Rule 10b5-1 plan, indicating it was scheduled in advance to cover tax withholding on vesting restricted stock units.